Uncovered by a study, METTL3 with high expression in GC was corelated with the poor outcomes of patients and high malignancy in vitro and in vivo, which showed preferred sensitivity to everolimus and activated mTOR pathway. This evidence concerns the gene METTL3 and gastric cancer.